Journal of Alzheimer's Disease
School of Medicine
U.S. Food and Drug Administration-s (FDA) approval of aducanumab (Aduhelm® in the US) as a treatment for mild cognitive impairment of the Alzheimer type and Alzheimer-s disease has raised such major concerns about efficacy, safety, FDA processes, and regulatory capture that Biogen-s license to market this biologic should be immediately withdrawn. Aducanumab has not demonstrated benefit to patients, failed to meet regulatory guidelines, and is likely to cause both individual and societal harm.
© Whitehouse & Vikas, 2022. The definitive, peer reviewed and edited version of this article is published in Journal of Alzheimer's Disease, vol. 87, no. 3, pp. 999-1001, 2022, https://doi.org/10.3233/JAD-220264.
Whitehouse, Peter J., "Making the Case for the Accelerated Withdrawal of Aducanumab" (2022). Faculty Scholarship. 59.
Neurology Commons, Neurosciences Commons, Psychiatry and Psychology Commons, Public Health Commons
This is an Accepted Manuscript of an article published by IOS Press in the Journal of Alzheimer's Disease on May 31, 2022, available at: https://doi.org/10.3233/JAD-220264